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Abstract – Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in dogs and
cats were investigated in an unmatched case-control study. A total of 197 animals from 150 veterinary
practices across the United Kingdom was enrolled, including 105 MRSA cases and 92 controls with
methicillin-susceptible S. aureus (MSSA) infection. The association of owners and veterinarian staff with
the human healthcare sector (HCS) and animal-related characteristics such as signalment, antimicrobial
and immunosuppressive therapy, and surgery were evaluated as putative risk factors using logistic
regression. We found that significant risk factors for MRSA infection were the number of antimicrobial
courses (p = 0.005), number of days admitted to veterinary clinics (p = 0.003) and having received
surgical implants (p = 0.001). In addition, the odds of contact with humans which had been ill and
admitted to hospital (p = 0.062) were higher in MRSA infected pets than in MSSA controls. The risk
factors identified in this study highlight the need to increase vigilance towards identification of
companion animal groups at risk and to advocate responsible and judicious use of antimicrobials in small
animal practice.
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1. INTRODUCTION
Methicillin-resistant Staphylococcus aureus
(MRSA) remains an important nosocomial
pathogen by contributing to health and
economic burdens on human patients and
health-care systems (HCS) worldwide [49, 50].
In humans, contact with HCS facilities is
commonly documented as an independent risk
factor for MRSA carriage or infection [21, 23,
27, 31]. Also, the selection pressure exerted
by the use of antimicrobial therapy is a well
documented risk factor, especially with the
use of cephalosporins and fluoroquinolones* Corresponding author: r.magalhaes@sph.uq.edu.au
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[24, 42, 48, 51]. Additionally, overcrowding and
understaffing leads to the failure of MRSA con-
trol programmes in humanhospitalswhich could
becontributing to the spill-over of infection to the
community [13].
For many years, MRSAwas considered only
a human pathogen. It has now become an
increasingly urgent problem in veterinary
medicine, with infections being reported in
companion and food animal species (i.e. dogs,
horses, cats, pet birds, cattle and pigs) [7, 28,
44]. In late 2003 and early 2004, it became
apparent that MRSA infection in the UK was
much more widespread in dogs and cats than
previously thought [36]. Worldwide there is
an increase in the number of reported MRSA
clinical infections in veterinary practices which
suggests that either there is increased aware-
ness about MRSA infection in veterinary
practices – leading to increased diagnosis and
detection – or companion animals such as dogs,
cats and horses, have become increasingly
exposed and susceptible to MRSA and are
now a potential reservoir of infection to humans
[11, 32, 38].
Given the close social interaction between
companion animals and humans it is expected
that contact with human carriers such as at
home or at the veterinary practice would be
linked to MRSA acquisition by a pet. Also,
the transmission of MRSA strains between dif-
ferent host species has previously been
described in the context of households (i.e.
between owners and their pets) and veterinary
practices (i.e. between veterinary personnel
and pets) [11, 32, 41, 47]. Mucosal carriage
of MRSA in otherwise healthy attending veter-
inary staff, owners and human-health care
workers has been demonstrated in numerous
studies [12, 21, 26, 29, 32, 39, 43, 45, 46].
Transfer between humans and animals has
been corroborated by typing studies which
showed that MRSA from dogs and cats
were typically identical to hospital-associated
lineages dominant in the particular countries
[6, 33, 40].
To the best of our knowledge, human-related
risk factors associated with MRSA infection in
dogs and cats have not been adequately investi-
gated. Their identification may facilitate the
design of appropriate infection control and pre-
vention strategies in veterinary practices with
additional benefits for public health. This
would allow a better understanding of MRSA
epidemiology in these species which would
inform revision of the current recommendations
for the control of this important zoonotic agent
in humans by including animal-related control
measures. We hypothesise that the risk of
MRSA infection in dogs and cats is determined
by factors of the companion animals’ clinical
history and the contact with humans associated
with the HCS.
This study aims to identify risk factors for
MRSA infection in dogs and cats by investi-
gating animal-related characteristics such as
signalment (e.g. species, sex, age, and body
weight), medication and veterinary interven-
tion and in-contact human association with
the HCS.
2. MATERIALS AND METHODS
2.1. Study groups and data collection
An unmatched population-based case-control
study was conducted including dogs and cats with
MRSA infection (cases) and those with methicillin-
susceptible S. aureus (MSSA) as controls. Previous
case-control studies in humans and animals have
often used subjects with MSSA infection/coloniza-
tion as a control group since it is considered a justi-
fiable assumption that these individuals come
from the same source population as MRSA cases
[19, 22, 24, 27].
We used a population database available at one of
the largest diagnostic laboratories currently operating
in the UK (IDEXX Laboratories, Wetherby, UK) to
minimize selection biases that could arise from
difficulties in enumeration of the source population.
Animals were identified from clinical specimens
submitted to the veterinary laboratory for bacterial
culture and antimicrobial susceptibility testing. Sam-
ples had been submitted by veterinary surgeons
across the UK between October 2005 and October
2007 as part of their diagnostic investigations into
suspected bacterial infection. For all consecutive
S. aureus isolations during that period (single submis-
sions from different animals) laboratory staff
requested permission from the submitting veteri-
nary surgeon to pass on practice details and animal
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identification to the authors. The authors then invited
the veterinary surgeons to participate in the study and
study material (consent forms, questionnaires, swabs)
were sent to the practice. The veterinary surgeons
were asked to recruit up to four volunteering people
(ideally two veterinary staff, two pet owners) in
contact with the respective infected animal. Where
close contact with more than four volunteering peo-
ple was identified, study material was provided for
an additional two humans. Participants were asked
to complete a questionnaire on healthcare-associa-
tions and submit a nasal swab. Validated question-
naires were used to gather information on direct or
indirect contact with human health care system
facilities (i.e. work within the human healthcare
sector, contact with healthcare workers or people with
known MRSA carriage or infection, participant’s
health status including antimicrobial therapy, visits
to healthcare facilities) for the 6-month period
prior to enrolment. Methods and detailed results
of the human nasal swabbing are described
separately [30].
Animal medical histories were requested for each
animal covering the 6-month period prior to S. aureus
isolation.
2.2. Ethics
The sampling procedures in animals and in
humans had been approved by the Royal Veterinary
College Ethics Committee and the National Research
Ethics Service (NRES) (formerly Central Office for
Research Ethics Committees), respectively. Follow-
ing their written consent, participants would code
their nasal swab prior to laboratory submission. Con-
sent forms with participants’ details and coded swab
results were collected by the authors who informed
all participants of their nasal swab results in writing
together with a recommendation to discuss any posi-
tive results with their doctors. Owners’ details were
deleted from their animal’s medical histories if they
were not participating.
2.3. Culture of samples
All clinical samples from animals and subsequent
human nasal swabs (as described in [30]) were ini-
tially processed by IDEXX Laboratories. Staphylo-
coccal isolation and identification was based on a
combination of routine microbiological tests, auto-
mated speciation and antimicrobial susceptibility test-
ing (Vitek2, bioMe´rieux, Hazelwood, MO, USA) and
by latex agglutination testing for the detection of
penicillin-binding protein 20 (Oxoid, Basingstoke,
UK). Animal and human S. aureus were subse-
quently confirmed at the Royal Veterinary College
phenotypically (colony morphology assessment,
Gram staining, slide and tube coagulase tests, DNase
test, Voges–Proskauer reaction, lactose and trehalose
fermentation) and genotypically using demonstration
of the species-specific thermonuclease gene (nuc) by
polymerase chain reaction (PCR) [8]. MRSA
were identified from growth on mannitol salt agar
(Oxoid) supplemented with 6 mg/L of oxacillin
(Sigma-Aldrich, Gillingham, UK) and confirmed by
disc diffusion tests with methicillin (5 lg, Oxoid)
on Mueller–Hinton agar (Oxoid) incubated for
24 h at 30 C following the Clinical and Laboratory
Standards Institute guidelines [14], and by molecular
confirmation of the presence of mecA by PCR [10].
All S. aureus isolates were typed based on character-
isation of their lineage-specific restriction modifica-
tion system (RM) [15].
2.4. Statistical analysis
All statistical analyses were carried out using the
statistical software Stata SE Version 9.2 (Stata
Corporation, College Station, TX, USA). Data were
collected for 12 animal-related variables from pets’
medical histories (Tab. I) and for 19 human health-
care-related variables from questionnaires (Tab. II).
The statistical analysis was carried out in two phases
using S. aureus infection status of the animal
(i.e. MRSA case or MSSA control) as the outcome
variable of interest.
Firstly, all putative human-healthcare-association
and all animal related risk factors were screened
using univariable logistic regression for statistical
association with animal MRSA infection status based
on a liberal p-value of 0.20 in the likelihood-ratio
test.
Secondly, all risk factors significant in the screen-
ing phase were considered for inclusion through a
manual backward stepwise variable selection process
in a multivariable logistic regression analysis. The
criterion for removal of risk factors was based on sta-
tistical considerations using the likelihood ratio test
with a significance level of p > 0.05.
The impact of clustering of cases and controls by
veterinary practice was assessed in the univariable
and in the multivariable analysis by including ‘‘veter-
inary practice postal code’’ as a random effect using
the XTLOGIT command in Stata estimating the sta-
tistical significance of intraclass correlation coeffi-
cient, q. The final model was assessed for potential
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Table I. Univariable analysis of associations between MRSA infection status (i.e. MRSA case and MSSA
control) in 181 dogs and cats and attributes of their clinical history (based on available medical records)
during the 6 months prior to sample submission, using animal as the unit of analysis and veterinary practice
as a random effect. For variables with two categories the p-value is provided where as for variables with
more than two categories an overall p-value based on a Wald-test is provided.
Variable level MRSA
n (%)
MSSA
n (%)
OR 95% CI p-value Overall
p-value
Species
Dogs 70 (70.71) 47 (57.32) Ref.
Cat 29 (29.29) 35 (42.68) 0.5 0.20–1.23 0.131
Sex
Female 49 (49.50) 37 (45.12) Ref.
Male 50 (50.50) 45 (54.88) 0.83 0.35–1.98 0.67
Age in years
< 2 22 (23.91) 21 (26.58) Ref. 0.749
2 to 5 26 (28.26) 17 (21.52) 1.07 0.28–4.16 0.919
5 to 9 20 (21.74) 23 (29.11) 0.6 0.16–2.31 0.455
> 9 24 (26.09) 18 (22.78) 1.19 0.31–4.59 0.798
Body weight
< 15 kg 39 (43.33) 44 (58.67) Ref.
> 15 kg 51 (56.67) 31 (41.33) 2.03 0.81–5.08 0.13
Number of visits to veterinary practice*
Once 8 (8.16) 16 (19.51) Ref. 0.126
2 to 4 29 (29.59) 26 (31.71) 2.73 0.69–10.87 0.154
> 5 61 (62.25) 40 (48.78) 3.79 1.05–13.75 0.043
Number of days admitted to veterinary practice
None 8 (8.08) 30 (36.58) Ref. 0.001
1 28 (28.28) 38 (46.34) 3.82 0.96–15.30 0.058
> 1 63 (63.64) 14 (17.07) 35.41 6.04–207.55 0.001
Number of antimicrobial courses
None 8 (8.09) 25 (30.49) Ref. 0.01
1 31 (31.31) 24 (29.27) 6.06 1.50–24.50 0.011
2 30 (30.30) 23 (28.05) 5.37 1.34–21.52 0.018
> 3 30 (30.30) 10 (12.20) 19.75 3.41–114.44 0.001
Topical antimicrobial therapy
No 65 (65.66) 58 (70.73) Ref.
Yes 34 (34.34) 24 (29.27) 1.53 0.57–4.09 0.394
Systemic glucocorticoid therapy
Yes 16 (16.16) 17 (20.73) Ref.
No 83 (83.84) 65 (79.27) 1.23 0.40–3.75 0.722
Surgical implant
No 71 (71.72) 80 (97.56) Ref.
Yes 28 (28.28) 2 (2.44) 49.4 4.38–556.60 0.002
Duration of infection*
< 2 months 72 (72.73) 48 (58.54) Ref.
> 2 months 27 (27.27) 34 (41.46) 0.45 0.17–1.19 0.106
Concurrent chronic disease*
No 61 (61.62) 38 (46.34) Ref.
Yes 38 (38.38) 44 (53.66) 0.36 0.12–1.01 0.053
Ref.: reference category; OR: odds ratio; CI: confidence interval.
* Number of visits to veterinary practice: number of outpatient visits in 6 months prior to swab; Duration of
infection: duration of clinical signs compatible with infection at sampling site; Concurrent chronic disease: chronic
non-communicable conditions not associated with MRSA or MSSA infection. These included, but were not
limited to endocrinopathy, heart disease, degenerative joint disease.
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confounders amongst the removed variables by
individually assessing their impact on the coeffi-
cients of the included variables. If the coefficient
of one these variables changed by more than
25%, the eliminated variable was assumed to be a
confounder and forced back into the model. We also
assessed the coefficient of determination, R-squared,
of the main effects model. Biologically meaningful
first-order interaction terms were also tested for
statistical significance. The goodness-of-fit of the
final multivariable model was tested using the
Hosmer–Lemeshow test [20].
3. RESULTS
3.1. S. aureus infection in dogs and cats
Bacteriological results and questionnaire
information were available for 197 dogs and
cats from a total of 150 practices (Fig. 1)
corresponding to 105 MRSA cases and 92
MSSA controls; most practices (79%, n = 119)
contributed one animal, 18 practices contributed
two animals each, 10 practices three animals
each and 3 practices four animals each. The rea-
sons for refusal among submitting veterinary
surgeons were concerns about time commit-
ment and stigma effect on the private practice,
while for owners it was the perceived inconve-
nience of the investigators’ requests. With
respect to human survey participation, aiming
at least one human participant per animal, we
were able to obtain 77% participation for
MRSA cases and 74% for MSSA control ani-
mals. On average, each MRSA case and each
MSSA control had 3 participating in-contact
humans; more precisely, 6 in-contact humans
were available for 2 animals, 5 for 4 animals,
4 for 82 animals, 3 for 41 animals, 2 for
55 animals and 1 in-contact human for each
of 13 animals. Assuming that a maximum of
788 human participants could have participated,
the overall human participation percentage was
76.5% (94.2% for veterinary staff, 54.6% for
pet owners). In addition, clinical histories were
collected for a total of 181 animals, correspond-
ing to 99 MRSA cases and 82 MSSA controls.
Reasons given for non-participation of veteri-
nary staff included time concerns or a very
short contact history with the pet (e.g. animal
visiting practice once while on holidays, attend-
ing veterinary staff left practice). Analysis of
animal clinical histories has shown that 76%
(137/181) of animals enrolled had used at least
one course of beta-lactam antimicrobial in the
last 6 months preceding the sampling whilst flu-
oroquinolones had been used in 28% (51/181)
of animals and 84% (43/51) of these had also
been administered at least one course of beta-
lactam antimicrobial.
3.2. Univariable analysis
We investigated the strength of association
between the infection status of dogs and cats
enrolled in the study with (1) factors related
to their recent clinical history and (2) in-contact
person factors (i.e. their links to the HCS
facilities).
At a p  0.20, MRSA infection status in
animals was associated with 8 animal medical
history related factors (Tab. I) and 6 in-contact
person factors (Tab. II).
3.3. Multivariable analysis
The final multivariable model was based on
176 records. The following variables were
retained significant at a p < 0.05: ‘‘Number
of antimicrobial courses’’, ‘‘Number of days
admitted to the veterinary practice’’, ‘‘Ongoing
infection’’, ‘‘Surgical implant’’, and an interac-
tion term between ‘‘Contact with at least two
ill humans’’ and ‘‘Contact with at least one
human admitted to hospital’’ (Tab. III). The
inclusion of ‘‘veterinary practice postal code’’
as a random effect into the final multivariable
model did not improve model fit. The good-
ness-of-fit of the final multivariable model to
the data, as assessed by the Hosmer–Lemeshow
goodness of fit test, was adequate (p = 0.764).
4. DISCUSSION
This study provides for the first time a com-
prehensive investigation of risk factors for
MRSA infection in dogs and cats from first
opinion practices and their human in-contacts.
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(page number not for citation purpose) Page 5 of 12
Table II. Univariable analysis of associations between MRSA infection status (i.e. MRSA case and MSSA
control) in 197 dogs and cats and attributes of their in-contact humans with respect to links to human health-
care system (HCS) facilities, during the 6 months prior to sample submission, using animal as the unit of
analysis and veterinary practice as a random effect.
Variable level MRSA n (%) MSSA n (%) OR 95% CI p-value
At least one human in-contact works at HCS
No 68 (64.76) 54 (58.70) Ref.
Yes 37 (35.24) 38 (41.30) 0.77 0.37–1.59 0.476
At least two human in-contacts work at HCS
No 96 (91.43) 80 (86.96) Ref.
Yes 9 (8.57) 12 (13.04) 0.64 0.20–2.01 0.446
At least one human in-contact was ill
No 43 (40.95) 29 (31.52) Ref.
Yes 62 (59.05) 63 (68.48) 0.64 0.30–1.36 0.249
At least two human in-contacts were ill
No 86 (81.90) 67 (72.83) Ref.
Yes 19 (18.10) 25 (27.17) 0.55 0.23–1.30 0.174
At least one in-contact human has been visited by HCS workers
No 54 (51.43) 57 (61.96) Ref.
Yes 51 (48.57) 35 (38.04) 2 0.89–4.49 0.092
At least two in-contact humans have been visited by HCS workers
No 88 (83.81) 81 (88.04) Ref.
Yes 17 (16.19) 11 (11.96) 1.67 0.58–4.82 0.346
At least one in-contact human lives with ill person
No 90 (85.71) 84 (91.30) Ref.
Yes 15 (14.29) 8 (8.70) 1.9 0.61–5.98 0.271
At least one in-contact human has been admitted to hospital
No 40 (38.10) 51 (55.43) Ref.
Yes 65 (61.90) 41 (44.57) 2.48 1.15–5.35 0.021
At least two in-contact humans have been admitted to hospital
No 89 (84.76) 78 (84.78) Ref.
Yes 16 (15.24) 14 (15.22) 1.04 0.39–2.77 0.936
At least one in-contact human has been to GP
No 11 (10.48) 5 (5.43) Ref.
Yes 94 (89.52) 87 (94.57) 0.43 0.10–1.75 0.236
At least two in-contact humans have been to GP
No 37 (35.24) 28 (30.44) Ref.
Yes 68 (64.76) 64 (69.56) 0.73 0.32–1.64 0.45
At least three in-contact human have been to a GP
No 69 (65.71) 61 (66.30) Ref.
Yes 36 (34.29) 31 (33.70) 1.19 0.54–2.58 0.668
At least one in-contact human has been to a dentist
No 13 (12.38) 15 (16.30) Ref.
Yes 92 (87.62) 77 (83.70) 1.56 0.53–4.53 0.418
At least two in-contact humans have been to a dentist
No 50 (47.62) 53 (57.61) Ref.
Yes 55 (52.38) 39 (42.39) 1.9 0.84–4.30 0.124
At least three in-contact humans have been to dentist
No 79 (75.24) 76 (82.61) Ref.
Yes 26 (24.76) 16 (17.39) 1.79 0.73–4.36 0.201
Continued on next page
Vet. Res. (2010) 41:55 R.J. Soares Magalha˜es et al.
Page 6 of 12 (page number not for citation purpose)
We identified the following risk factors: number
of antimicrobial courses, number of days admit-
ted to the veterinary practices, ongoing infec-
tion (for less than 2 months), surgical implant,
and contact with humans who had been ill
and had been admitted to hospital. These risk
factors broadly mirror those described for
MRSA infections in humans which suggests
that the aetiology of staphylococcal infections
is likely to be similar in these hosts.
Responsible and judicious use of antimicrobi-
als is an essential part of an ethical approach to
improving companion health and welfare [25].
This includes avoiding empirical antimicrobial
therapy (i.e. therapy initiated on the basis of
observation of clinical signs and patient history
only) without confirmation of diagnosis by labo-
ratory or othermethods. The use of repeated anti-
microbial therapy has been previously identified
as a risk factor for inducing selection pressures
in favour of MRSA strains in humans [24, 42,
48, 51]. Our results suggest that dogs and cats
with MRSA infections are more likely to have
received more than three courses of antimicrobi-
als within the 6 months prior to isolation of
MRSA than MSSA controls. This observed
association may be a consequence of repeated
empirical therapy and selection in favour of
MRSA strains; alternatively, if animals had
MRSA, it is likely that practitioners attempted
multiple antimicrobial courses to treat infection.
These results are consistentwith a recent study in
3 veterinary referral hospital in the USA where
specific antimicrobial drugs were identified as
significant risk factors for MRSA infection in
dogs [22].
The use of certain types of antimicrobial
drugs (namely, cephalosporins and fluoroquino-
lones) has been shown to contribute to selection
of MRSA strains in humans [17, 48] and has
been found to be a risk factor for MRSA infec-
tion in dogs [22]. Recently there have been calls
for banning of use of these antimicrobials by vet-
erinary practitioners as a means for reducing
selection pressures and alleviating MRSA infec-
tion burden in humans [4, 34]. In our study the
use of fluoroquinolones, which are known to
be ineffective against UK hospital MRSA and
may contribute to selection, was limited when
compared to the usage of beta-lactam antimicro-
bials and they were often used in combination
with at least one course of beta-lactam antimicro-
bial. However, due to the low variability of anti-
microbial usage in our sample our findings do
not provide sufficient evidence to inform
whether specific antimicrobial practice usage
profiles in the UK are associated with increased
risk of MRSA infection and therefore further
studies are needed in this domain. Regula et al.
have investigated the antimicrobial usage pro-
files of eight mixed veterinary practices (small
animals and large-animals) in Switzerland and
found that veterinarians judiciouslyused the anti-
microbials of highest importance for the treat-
ment of humans (i.e. fluoroquinolones,
third- and fourth-generation cephalosporins and
Table II. Continued.
Variable level MRSA n (%) MSSA n (%) OR 95% CI p-value
At least one in-contact human has been to a nursing home
No 77 (73.33) 63 (68.48) Ref.
Yes 28 (26.67) 29 (31.52) 0.76 0.34–1.70 0.508
At least one in-contact human has taken antimicrobials
No 42 (40) 32 (34.78) Ref.
Yes 63 (60) 60 (65.22) 0.76 0.36–1.61 0.466
At least two in-contact humans have taken antimicrobials
No 84 (80) 66 (72.53) Ref.
Yes 21 (20) 25 (27.47) 0.57 0.23–1.41 0.222
At least one in-contact human has taken immunosuppressant therapy
No 87 (82.86) 82 (90.11) Ref.
Yes 18 (17.14) 9 (9.89) 2.04 0.70–5.95 0.19
Ref.: reference category; OR: odds ratio; CI: confidence interval; GP: general practitioner.
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Figure 1. Geographical distribution of 150 practices enrolled in the study during October 2005 to October
2007 for which complete georeference information was retrieved. Practices contributing an MRSA case,
an MSSA control or both are depicted as red (black), green (grey) and blue (dark) dots, respectively.
(For a color version of this figure, please consult www.vetres.org.)
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macrolides), as recommended by prudent usage
guidelines [35]. Furthermore, for the protection
of human health, ongoing joint activities of the
World Organization for Animal Health (OIE),
Food and Agricultural Organization of the
UnitedNations (FAO) andWorldHealthOrgani-
zation (WHO) have led to the elaboration of
numerous international guidelines on responsi-
ble and judicious use of antimicrobial agents in
animals [18, 34]1,2. An important spin-off from
this consultative process was the establishment
of a Codex Alimentarius Ad Hoc Intergovern-
mental Task Force on Antimicrobial Resistance
which primarily seeks to define a list of critical
antimicrobials used in human and food animal
veterinary medicine. However, similar efforts
are still absent in the context of companion
animal veterinary medicine both at national and
international level.
The results of our study also suggest that
MRSA infected dogs and cats are five times
more likely than MSSA infected pets to have
been admitted to the veterinary practice for a
duration of more than one day. In humans,
length of stay as measured by number of days
admitted to hospital has been identified as a risk
factor for MRSA infection as well as a result of
MRSA infection [1, 16]. Because animals were
not examined for MRSA carriage or infection
prior to admission to the respective veterinary
practice the results cannot explain whether
Table III. Risk factors for MRSA infection in dogs and cats retained in the final multivariable logistic
regression model based on 176 records using animal as the unit of analysis (R2 = 0.35). For variables with
two categories the p-value is provided where as for variables with more than two categories an overall
p-value based on a Wald-test is provided.
Variable Level OR 95% CI p-value Overall p-value
Number of antimicrobial courses 0.005
None Ref.
1 4.45 1.26–15.77 0.021
2 5.78 1.54–21.65 0.009
> 3 17.31 3.59–83.48 < 0.001
Number of days admitted 0.003
None Ref.
1 1.32 0.44–3.97 0.619
> 1 5.27 1.62–17.10 0.006
Duration of infection
< 2 months Ref.
> 2 months 0.20 0.08–0.53 0.001
Surgical implant
No Ref.
Yes 32.98 4.59–236.86 0.001
At least two human in-contacts were ill (A)
No Ref.
Yes 0.11 0.02–0.78 0.027
At least one in-contact human has been admitted to hospital (B)
No Ref.
Yes 1.48 0.62–3.55 0.381
Interaction term: A*B 8.51 0.85–85.16 0.062
Ref.: reference category; OR: odds ratio; CI: confidence interval.
1 FAO/WHO/OIE, WHO global principles for the
containment of antimicrobial resistance in animals
intended for food, 2000. Available from http://
whqlibdoc.who.int/hq/2000/WHO_CDS_CSR_APH_
2000.4.pdf [cited 25 March 2010].
2 Codex-Alimentarius, Code of practice to mini-
mize and contain antimicrobial resistance, 2005.
Available from http://www.codexalimentarius.net/
download/standards/10213/CXP_061e.pdf [cited
25 March 2010].
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MRSA infection prolonged admission or
whether MRSA infection was a result of pro-
longed length of stay at the practice.
The linkage of owners and veterinarians to
HCS facilities has been suggested as a pathway
through which animals are exposed to MRSA
strains [9, 32]3. We have identified nosocomial
linkage factors of in-contact humans (i.e. expo-
sure to HCS facilities) which were associated
with MRSA infection in dogs and cats. Previous
visits or admission to hospital are well-known
risk factors for human acquisition of MRSA in
the hospital setting [2, 5, 12, 27, 31, 37]. Our
results suggest that the odds of contact with at
least two ill in-contact humans and the hospital-
ization of at least one in-contact person is eight
times as likely in MRSA infected pets as it is
in MSSA controls. Although this result was
marginally significant (p = 0.062), it suggests
human exposure to HCS may contribute to the
epidemiology of MRSA infection in dogs and
cats. If hospitalization of in-contact humans
indeed has an effect onMRSA infection of dogs
and cats, having this information could lead to
modified practice management procedures prior
to admission of the animal to surgery.
The results of our study, particularly for
human in contact factors, have to be interpreted
cautiously taking into account that, only 70% of
MRSA cases and MSSA controls had informa-
tion about in-contact humans. Although, this
human participation percentage was similar or
better when compared to previous studies in
veterinary staff [3]4, this level of attrition may
have contributed to insufficient power for iden-
tifying significant associations between these
factors and MRSA infection in dogs and cats.
In summary, control efforts for reducing
MRSA infection in dogs and cats should be
aimed at reducing MRSA transmission amongst
veterinary personnel and within-practice envi-
ronmental contamination through promotion of
enhanced personal and practice hygiene, and cli-
ent education. This could be combined with
increased vigilance of animal groups at risk
identified in this study, e.g. admitted patients
and implant patients, and contact with recently
hospitalised humans which is expected to have
an impact on the reduction of within-practice
MRSA infection and transmission. In addition,
responsible and judicious use of antimicrobials
at the veterinary practice level should be
urgently advocated to significantly mitigate the
risk for dogs and cats developing MRSA infec-
tion. This would mean the early sampling of
infections in risk groups, avoidance of empirical
use of antimicrobial agents and use of antimicro-
bial therapy based on known sensitivity.
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